Pharvaris (PHVS) Income from Continuing Operations (2020 - 2026)
Pharvaris (PHVS) reported Income from Continuing Operations of 45574278.56 for Q1 2026, up 5.89% on a YoY basis from 43039096.55 in Q1 2025, and up 77.46% quarter-over-quarter from 202207598.07 in Q4 2025.
Pharvaris (PHVS) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Pharvaris has reported Income from Continuing Operations for 7 years, with the latest figure at 45574278.56 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 5.89% year-over-year to 45574278.56; the trailing twelve-month figure through Mar 2026 stood at 342662025.82 (down 111.85% YoY), and the FY2025 full-year result was 198507144.79, down 36.64% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 45574278.56, up from 202207598.07 in the prior quarter.
- The five-year high for Income from Continuing Operations was 10542483.8 in Q2 2022, with the low at 202207598.07 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 42447790.13 across 5 years, with a median of 34430026.52 in 2023.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations jumped 42.41% — and 2025, when it plunged 464.49%.
- Pharvaris' Income from Continuing Operations stood at 39680946.01 in 2022, then advanced by 13.23% to 34430026.52 in 2023, then fell by 4.04% to 35821184.65 in 2024, then sank by 464.49% to 202207598.07 in 2025, then jumped by 77.46% to 45574278.56 in 2026.
- The last three Income from Continuing Operations figures came in at 45574278.56 (Q1 2026), 202207598.07 (Q4 2025), and 43627387.1 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Pharvaris | 28.66 Bn | 28.37 Bn | - | -45.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.57 Mn |
| Dec 31, 2025 | -202.21 Mn |
| Sep 30, 2025 | -43.63 Mn |
| Jun 30, 2025 | -51.25 Mn |
| Mar 31, 2025 | -48.43 Mn |
| Dec 31, 2024 | -35.82 Mn |
| Sep 30, 2024 | -45.55 Mn |
| Jun 30, 2024 | -31.94 Mn |
| Mar 31, 2024 | -30.13 Mn |
| Dec 31, 2023 | -34.43 Mn |
| Sep 30, 2023 | -25.53 Mn |
| Jun 30, 2023 | -23.74 Mn |
| Mar 31, 2023 | -24.23 Mn |
| Dec 31, 2022 | -39.68 Mn |
| Sep 30, 2022 | -10.98 Mn |
| Jun 30, 2022 | -10.54 Mn |
| Mar 31, 2022 | -17.94 Mn |
| Dec 31, 2021 | -14.14 Mn |
| Sep 30, 2021 | -10.70 Mn |
| Jun 30, 2021 | -18.30 Mn |